Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (276)	9/25/1998 2:16:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 4974

Stuart: Regarding GLFD.... thanks, very interesting. I've thought that a dream merger would be NRGN and SIBI, two BVF companies. Jim Silverman throws in GLFD. So.... I'd merge NRGN, GLFD and SIBI, then I'd sell the whole caboodle to MLNM as Millennium Neuro Sciences. Chance of it happening? Not one, but it's fun to dream. I'm tired of great science languishing for lack of a manager or money. Rick

To: sim1 who wrote (276)	10/21/1998 1:06:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4974

Stuart: GLFD filed a revision of their rights offering a couple of days ago. Seems like minor revisions, based on a new Board structure. Nonetheless, it shows attention to it. Obligatory comments that are sort of on topic..... note from the 10/12 issue of F-D-C Reports (The Pink Sheet)..... "Disputing cynicism about the impact of genomics, Ringrose reported that almost 60% 'of the targets that we have at Bristol-Myers Squibb now come from genomic databases'." Peter Ringrose is President of BMS PRI. Rick